soul trial oral semaglutide cardiovascular outcomes results benefits of semaglutide: a systematic review and meta-analysis of randomized controlled trials | BMC Cardiovascular Disorders oral semaglutide cardiovascular benefit soul

The company is advancing higher-dose oral semaglutide formulations targeting obesity-level weight loss

It is not approved by the FDA (USA), the EMA (Europe), or the ANSM (France)

Manufacturer savings cards (Novo Nordisk and Lilly both offer programs), insurance coverage, the oral Wegovy tablet, and patient assistance programs

Medical weight loss provides a targeted, professional approach to achieving long-term weight management, especially as nearly 40% of American adults struggle with obesity

Nutritional therapies and herbs both improve GLP-1 activity and in many cases correct the numerous underlying contributors to metabolic dysfunction, through improving insulin sensitivity and satiety, supporting microbiome health and mitigating inflammation that can disrupt metabolic function